Misonix Exhibits at the Annual Paradigm Medical Management Meeting

Oct 23, 2013, 07:30 ET from Misonix, Inc.

FARMINGDALE, N.Y., Oct. 23, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently participated the 2013 Paradigm Medical Management Annual Meeting held in Indian Wells, CA from October 18th – 20th, 2013.

Misonix exhibited and presented the newest addition to its wound care line of devices, the SonicOne® O.R. Ultrasonic Surgical Debridement System, to medical directors and wound care program directors of Paradigm managed hospital programs. The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Use of the SonicOne O.R. system provides controlled tissue removal, improved healing times, reduced bleeding and a reduction of biofilm.

More than 100 participants attended a presentation by Lee C. Rogers, DPM, Medical Director of Amputation Prevention Programs for Paradigm Medical Management, where he featured the clinical benefits of SonicOne O.R. and the role it plays in the management of patients with wounds. Dr. Rogers commented, "This device is a no-brainer for our hospital programs. It debrides better and more selectively than existing technology and it's more cost effective."

Additionally, Diane Boone, Chief Executive officer of Paradigm Medical Management offered, "Our job as a management company is to help develop pathways to improve outcomes for healing wounds while improving the bottom line for the hospital. SonicOne does both and we're proud to work with Misonix to offer our hospital programs this advanced technology."

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix comments, "We are very pleased to see that our SonicOne O.R. technology is quickly gaining recognition by hospital systems and medical management systems such as Paradigm Medical Management as an important part of their treatment algorithm in their wound care programs. This level of interest speaks not only to the clinical importance of our technology but to the economics of treating these patients as well."

About Paradigm Medical Management

Paradigm Medical Management (PMM) is dedicated to the development, implementation, and management of hospital-based outpatient wound healing, amputation prevention and hyperbaric medicine programs. Paradigm is able to offer physicians and their patients access to the latest in technological innovations and best practice models.

With unique experience and expertise in managed care, including capitated environments and shared risk arrangements, Paradigm has developed a proven, successful strategy to provide managed care enrollees access to wound management and hyperbaric clinics within Paradigm-affiliated hospitals. Paradigm is expanding its network of amputation prevention centers under the umbrella of the Amputation Prevention Centers of America®. More information can be found on PMM's website at www.pmmhealthcare.com.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Misonix Contact:

Investor Contact:

Richard Zaremba

Joe Diaz


Lytham Partners




SOURCE Misonix, Inc.